FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3185087081> ?p ?o ?g. }

• W3185087081 endingPage "e1052" @default.
• W3185087081 startingPage "e1052" @default.
• W3185087081 abstract "To create an international consensus treatment recommendation for pediatric NMDA receptor antibody encephalitis (NMDARE).After selection of a panel of 27 experts with representation from all continents, a 2-step Delphi method was adopted to develop consensus on relevant treatment regimens and statements, along with key definitions in pediatric NMDARE (disease severity, failure to improve, and relapse). Finally, an online face-to-face meeting was held to reach consensus (defined as ≥75% agreement).Corticosteroids are recommended in all children with NMDARE (pulsed IV preferred), with additional IV immunoglobulin or plasma exchange in severe patients. Prolonged first-line immunotherapy can be offered for up to 3-12 months (oral corticosteroids or monthly IV corticosteroids/immunoglobulin), dependent on disease severity. Second-line treatments are recommended for cases refractory to first-line therapies (rituximab preferred over cyclophosphamide) and should be considered about 2 weeks after first-line initiation. Further immunotherapies for refractory disease 1-3 months after second-line initiation include another second-line treatment (such as cyclophosphamide) and escalation to tocilizumab. Maintenance immune suppression beyond 6 months (such as rituximab redosing or mycophenolate mofetil) is generally not required, except for patients with a more severe course or prolonged impairments and hospitalization. For patients with relapsing disease, second-line and prolonged maintenance therapy should be considered. The treatment of NMDARE following herpes simplex encephalitis should be similar to idiopathic NMDARE. Broad guidance is provided for the total treatment duration (first line, second line, and maintenance), which is dictated by the severity and clinical course (i.e., median 3, 9 and 18 months in the best, average, and worst responders, respectively). Recommendations on the timing of oncologic searches are provided.These international consensus recommendations for the management of pediatric NMDARE aim to standardize the treatment and provide practical guidance for clinicians, rather than absolute rules. A similar recommendation could be applicable to adult patients." @default.
• W3185087081 created "2021-08-02" @default.
• W3185087081 creator A5002367577 @default.
• W3185087081 creator A5012713039 @default.
• W3185087081 creator A5014802691 @default.
• W3185087081 creator A5015496072 @default.
• W3185087081 creator A5016970306 @default.
• W3185087081 creator A5023191804 @default.
• W3185087081 creator A5028137119 @default.
• W3185087081 creator A5030520617 @default.
• W3185087081 creator A5033920729 @default.
• W3185087081 creator A5034149246 @default.
• W3185087081 creator A5038335245 @default.
• W3185087081 creator A5039901601 @default.
• W3185087081 creator A5041774387 @default.
• W3185087081 creator A5043551657 @default.
• W3185087081 creator A5045704773 @default.
• W3185087081 creator A5053295756 @default.
• W3185087081 creator A5056193115 @default.
• W3185087081 creator A5056343821 @default.
• W3185087081 creator A5056717695 @default.
• W3185087081 creator A5058125590 @default.
• W3185087081 creator A5058661371 @default.
• W3185087081 creator A5067815402 @default.
• W3185087081 creator A5068251560 @default.
• W3185087081 creator A5079021764 @default.
• W3185087081 creator A5081804111 @default.
• W3185087081 creator A5083901106 @default.
• W3185087081 creator A5086940052 @default.
• W3185087081 creator A5087369332 @default.
• W3185087081 creator A5088549052 @default.
• W3185087081 date "2021-07-22" @default.
• W3185087081 modified "2023-10-10" @default.
• W3185087081 title "International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis" @default.
• W3185087081 cites W1895520487 @default.
• W3185087081 cites W1968634262 @default.
• W3185087081 cites W1969661146 @default.
• W3185087081 cites W1988612394 @default.
• W3185087081 cites W2022425641 @default.
• W3185087081 cites W2051552021 @default.
• W3185087081 cites W2060703516 @default.
• W3185087081 cites W2098001563 @default.
• W3185087081 cites W2098488998 @default.
• W3185087081 cites W2104956171 @default.
• W3185087081 cites W2117091873 @default.
• W3185087081 cites W2117181914 @default.
• W3185087081 cites W2118067546 @default.
• W3185087081 cites W2119088261 @default.
• W3185087081 cites W2119837784 @default.
• W3185087081 cites W2128903485 @default.
• W3185087081 cites W2146199022 @default.
• W3185087081 cites W2161118960 @default.
• W3185087081 cites W2163022996 @default.
• W3185087081 cites W2164776142 @default.
• W3185087081 cites W2187671472 @default.
• W3185087081 cites W2225011328 @default.
• W3185087081 cites W2278831696 @default.
• W3185087081 cites W2280783985 @default.
• W3185087081 cites W2289689860 @default.
• W3185087081 cites W2290012694 @default.
• W3185087081 cites W2291138108 @default.
• W3185087081 cites W2291699367 @default.
• W3185087081 cites W2336614583 @default.
• W3185087081 cites W2511370248 @default.
• W3185087081 cites W2515832988 @default.
• W3185087081 cites W2555682123 @default.
• W3185087081 cites W2562989187 @default.
• W3185087081 cites W2583829171 @default.
• W3185087081 cites W2589383916 @default.
• W3185087081 cites W2600364230 @default.
• W3185087081 cites W2745764093 @default.
• W3185087081 cites W2747686311 @default.
• W3185087081 cites W2758207576 @default.
• W3185087081 cites W2782996650 @default.
• W3185087081 cites W2790915271 @default.
• W3185087081 cites W2793290095 @default.
• W3185087081 cites W2802482160 @default.
• W3185087081 cites W2806804657 @default.
• W3185087081 cites W2807977394 @default.
• W3185087081 cites W2811440413 @default.
• W3185087081 cites W2883794780 @default.
• W3185087081 cites W2884179398 @default.
• W3185087081 cites W2909912770 @default.
• W3185087081 cites W2911872382 @default.
• W3185087081 cites W2928869984 @default.
• W3185087081 cites W2948961603 @default.
• W3185087081 cites W2956177188 @default.
• W3185087081 cites W2958851110 @default.
• W3185087081 cites W2962171619 @default.
• W3185087081 cites W2980350220 @default.
• W3185087081 cites W2999177463 @default.
• W3185087081 cites W3040705896 @default.
• W3185087081 cites W3083565327 @default.
• W3185087081 cites W4323236911 @default.
• W3185087081 doi "https://doi.org/10.1212/nxi.0000000000001052" @default.
• W3185087081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8299516" @default.
• W3185087081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34301820" @default.
• W3185087081 hasPublicationYear "2021" @default.

• next